Can a cholesterol-lowering combo also shrink fatty liver in diabetic heart patients?

NCT ID NCT07736313

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This trial investigates whether adding a PCSK9 inhibitor to a high-intensity statin can reduce liver fat—measured by a non-invasive FibroScan—in diabetic patients who have recently had a heart attack or unstable angina. Half the participants will receive the combination therapy, while the other half receive the statin alone. The goal is to see if the combination offers additional benefits for liver health and cholesterol control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a PCSK9 inhibitor (a cholesterol-lowering drug) plus rosuvastatin 20 mg tablet
What this could lead to
If it works, this could point toward a way to both lower cholesterol and reduce liver fat in diabetic heart patients, potentially lowering their risk of future heart problems.
What could go wrong
This is a small, early-phase trial (120 people) focused on a liver fat measurement, not on actual heart events. The added benefit over statins alone may be modest, and PCSK9 inhibitors can cause injection-site reactions or muscle pain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.